FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956006920> ?p ?o ?g. }

• W2956006920 endingPage "S54" @default.
• W2956006920 startingPage "S53" @default.
• W2956006920 abstract "Fabry disease (FD) is an X-linked inherited disorder resulting in accumulation of globotriaosylceramide (Gb3) that ultimately progresses to end-stage renal disease. Although the genetic basis of FD is well established, the pathophysiological mechanisms by which Gb3 storage leads to the FD phenotype remains unclear. It is well defined that the Gb3 accumulation in FD causes podocyte damage leading to fibrosis. To date, modelling of renal diseases and drug screening has utilised immortalised kidney cell lines which retain only limited characteristics of their somatic cell counterparts. Alternatively, primary podocytes are difficult to establish and maintain in culture. We therefore generated induced pluripotent stem cells (iPSC) by reprogramming human somatic cells from FD patients, with varying known FD mutations, to generate iPSCs followed by directed differentiation to podocytes that can be maintained long-term. Skin fibroblasts obtained from punch biopsies of patients with mapped FD mutations (n=3) compared to non-FD control patients (n=3) were obtained under informed consent. A NM-RNA reprogramming protocol that delivers transcription factors OCT3/4, TRA-1-60 and SSEA4 in lipofectamines through RNA transfection, was used to generate iPSCs. Pluripotency was confirmed by alkaline phosphatase staining and immunofluorescence staining performed using Oct4 and CSTEM 27, 28, 31. FD and control iPSCs were differentiated to podocytes following the addition of retinoic acid, bone morphogenic protein 7 and activin A. Day 10 iPSC-podocytes were immunostained for the expression of podocyte-specific markers – podocin and synaptopodin. Scanning electron microscopy (SEM) was performed on FD patient-derived iPSCs and control lines to observe podocyte morphological following differentiation and quantification of Gb3 performed using mass spectrometry (MS). Skin biopsy-derived dermal fibroblasts from FD and non-FD control patients were grown as monolayers and reprogrammed into iPSCs over 14 days, with pluripotency evident by alkaline phosphatase staining with normal karyotype confirmed. Colonies showed positive expression of pluripotency markers - Oct4 and CSTEM 27, 28 and 31. Directed differentiation of iPSCs resulted in the generation of podocytes over a period of 10 days that had an acquired typical podocyte morphology, consisting of either a single or multi-nucleated cell bodies and prominent foot processes. Day 10 iPSC-podocytes showed positive expression of podocyte-specific markers - podocin and synaptopodin. SEM imaging of differentiated iPSC-podocytes revealed primary and secondary foot processes, characteristic of kidney podocytes with no major morphological differences apparent between FD and control lines. Gb3 quantification using MS showed a varied increase in FD iPSC podocytes reflective of varied mutations associated with a range of pathologies and severity of disease, compared to non-FD cells. This study has generated iPSC from patients with FD that were differentiated to podocytes confirmed by morphological characteristics and podocyte marker localization. Understanding how mutations cause disease in FD using iPSC-derived kidney cells is a fundamental step for future studies to correct the genetic defects in these cells and as a valuable tool for use in disease modeling and toxicology screening." @default.
• W2956006920 created "2019-07-12" @default.
• W2956006920 creator A5024329184 @default.
• W2956006920 creator A5024815370 @default.
• W2956006920 creator A5031333482 @default.
• W2956006920 creator A5037344658 @default.
• W2956006920 creator A5079403340 @default.
• W2956006920 creator A5089701670 @default.
• W2956006920 date "2019-07-01" @default.
• W2956006920 modified "2023-10-06" @default.
• W2956006920 title "SAT-115 Generation and characterisation of induced pluripotent stem cells derived from patients with Fabry disease" @default.
• W2956006920 doi "https://doi.org/10.1016/j.ekir.2019.05.143" @default.
• W2956006920 hasPublicationYear "2019" @default.
• W2956006920 type Work @default.
• W2956006920 sameAs 2956006920 @default.
• W2956006920 citedByCount "1" @default.
• W2956006920 crossrefType "journal-article" @default.
• W2956006920 hasAuthorship W2956006920A5024329184 @default.
• W2956006920 hasAuthorship W2956006920A5024815370 @default.
• W2956006920 hasAuthorship W2956006920A5031333482 @default.
• W2956006920 hasAuthorship W2956006920A5037344658 @default.
• W2956006920 hasAuthorship W2956006920A5079403340 @default.
• W2956006920 hasAuthorship W2956006920A5089701670 @default.
• W2956006920 hasBestOaLocation W29560069201 @default.
• W2956006920 hasConcept C104317684 @default.
• W2956006920 hasConcept C107459253 @default.
• W2956006920 hasConcept C126322002 @default.
• W2956006920 hasConcept C142724271 @default.
• W2956006920 hasConcept C145103041 @default.
• W2956006920 hasConcept C1491633281 @default.
• W2956006920 hasConcept C2776855237 @default.
• W2956006920 hasConcept C2777117487 @default.
• W2956006920 hasConcept C2777146197 @default.
• W2956006920 hasConcept C2777404818 @default.
• W2956006920 hasConcept C2777687718 @default.
• W2956006920 hasConcept C2777933648 @default.
• W2956006920 hasConcept C2779134260 @default.
• W2956006920 hasConcept C2779561371 @default.
• W2956006920 hasConcept C2780091579 @default.
• W2956006920 hasConcept C2910727860 @default.
• W2956006920 hasConcept C502942594 @default.
• W2956006920 hasConcept C54355233 @default.
• W2956006920 hasConcept C71924100 @default.
• W2956006920 hasConcept C77255625 @default.
• W2956006920 hasConcept C86803240 @default.
• W2956006920 hasConcept C95444343 @default.
• W2956006920 hasConceptScore W2956006920C104317684 @default.
• W2956006920 hasConceptScore W2956006920C107459253 @default.
• W2956006920 hasConceptScore W2956006920C126322002 @default.
• W2956006920 hasConceptScore W2956006920C142724271 @default.
• W2956006920 hasConceptScore W2956006920C145103041 @default.
• W2956006920 hasConceptScore W2956006920C1491633281 @default.
• W2956006920 hasConceptScore W2956006920C2776855237 @default.
• W2956006920 hasConceptScore W2956006920C2777117487 @default.
• W2956006920 hasConceptScore W2956006920C2777146197 @default.
• W2956006920 hasConceptScore W2956006920C2777404818 @default.
• W2956006920 hasConceptScore W2956006920C2777687718 @default.
• W2956006920 hasConceptScore W2956006920C2777933648 @default.
• W2956006920 hasConceptScore W2956006920C2779134260 @default.
• W2956006920 hasConceptScore W2956006920C2779561371 @default.
• W2956006920 hasConceptScore W2956006920C2780091579 @default.
• W2956006920 hasConceptScore W2956006920C2910727860 @default.
• W2956006920 hasConceptScore W2956006920C502942594 @default.
• W2956006920 hasConceptScore W2956006920C54355233 @default.
• W2956006920 hasConceptScore W2956006920C71924100 @default.
• W2956006920 hasConceptScore W2956006920C77255625 @default.
• W2956006920 hasConceptScore W2956006920C86803240 @default.
• W2956006920 hasConceptScore W2956006920C95444343 @default.
• W2956006920 hasIssue "7" @default.
• W2956006920 hasLocation W29560069201 @default.
• W2956006920 hasOpenAccess W2956006920 @default.
• W2956006920 hasPrimaryLocation W29560069201 @default.
• W2956006920 hasRelatedWork W1788736447 @default.
• W2956006920 hasRelatedWork W2082218620 @default.
• W2956006920 hasRelatedWork W2139698846 @default.
• W2956006920 hasRelatedWork W2142648384 @default.
• W2956006920 hasRelatedWork W2197510689 @default.
• W2956006920 hasRelatedWork W2333517425 @default.
• W2956006920 hasRelatedWork W2560446420 @default.
• W2956006920 hasRelatedWork W2891095785 @default.
• W2956006920 hasRelatedWork W2913956759 @default.
• W2956006920 hasRelatedWork W2956006920 @default.
• W2956006920 hasVolume "4" @default.
• W2956006920 isParatext "false" @default.
• W2956006920 isRetracted "false" @default.
• W2956006920 magId "2956006920" @default.
• W2956006920 workType "article" @default.